A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C

Model scores of the 29,894 trials active now.

Model score 4% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 6% of the time (776 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: tolerabilityto determinesubject hasabtsubject is
  Phrases that lowered it: healthymalevolunteersfemalepharmacokinetics
• Primary purpose: not given (lowers risk) · Design
• Phase: 1 (lowers risk) · Design
• Sponsor's past termination rate: 10% (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 45 (lowers risk) · Sponsor's track record
• Responsible party: not given (raises risk) · Design
• Drug's FAERS reports with a death: 13.5% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: 55 (lowers risk) · Who can join
• Blinding: quadruple (raises risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Drug's FAERS reports marked serious: 89.9% (raises risk) · Drug's FDA history
• Sponsor's past trials: 60 (lowers risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of Single Doses of ABT-072 in Japanese Healthy Male Adults NCT01081483 · started 2010 · scored riskier than 6% of active trials completed
• Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072 NCT00982826 · started 2009 · scored riskier than 6% of active trials completed
• A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults NCT00752687 · started 2008 · scored riskier than 6% of active trials completed
• Study of ABT-267 in Both Healthy Volunteers and Hepatitis C Virus (HCV) Genotype 1 Infected Subjects NCT01181427 · started 2010 · scored riskier than 5% of active trials completed
• A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ABT-333 NCT00768690 · started 2008 · scored riskier than 4% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.